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Factors affecting host immunity are important variables
during cancer growth. The immunosuppressive tumor
microenvironment perturbs numerous immune regula-
tory networks and usurps host antitumor immune
responses. We discovered that tumor interferes with
host hematopoietic Notch system. Tumor-induced
decrease in Notch signaling in host immune cells could
be a major causative link in the inadequate induction of
anti-tumor immunity. Interestingly, we found that
tumor-induced decrease in immune Notch could be
restored therapeutically by the following two agents.
Administration of a novel Delta-like ligand 1 (DLL1)
multivalent cluster, and FDA-approved proteasome inhi-
bitor drug bortezomib - which also sensitizes tumors to
death signals - could activate Notch 1 signaling in lym-
phoid cells of tumor-bearing mice without increasing
tumor cell proliferation or clonogenicity. Systemic acti-
vation of DLL1-Notch signaling could attenuate tumor
vascularization as well as increase T cell infiltration in
tumor, decrease proportion of regulatory T cells and
enhance antitumor T cell function and memory in mul-
tiple mouse tumor models. This resulted in significant
suppression of tumor growth in wild type mice as well
as provided therapeutic benefit following an adoptive
T cell transfer into tumor-bearing SCID-NOD mice.
New data also show that bortezomib affects the expres-
sion of notch receptors and ligands differentially in lym-
phocytes and in a wide range of solid tumor cells: 4T1,
PyMT, MDA-MB-231, C26, LLC, D459, and Renca-HA.
Moreover, bortezomib administration increased the
expression of Notch target Hes1 in thymus, lymph node
and spleen of tumor-bearing mice, suggesting a potential
synergistic action of bortezomib and DLL1 activation of
Notch signaling. This new role of Notch in the develop-
ment of effective antitumor immunity and the potential
of its modulation by a novel prototypic agent DLL1 in
combination with bortezomib present exciting opportu-
nities to uncover multi-pronged immune stimulatory
regimens. Reagents based on the multivalent forms of
Notch ligands thus need to be explored for the thera-
peutic modulation of Notch signaling. Therapeutic
restoration of immune Notch signaling could provide
effective treatment and recurrence-free survival in can-
cer patients by breaking tumor resistance and induction
of robust antitumor immunity.
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